Blosozumab
Blosozumab (LY2541546) is an anti-Human sclerostin (SOST) antibody inhibitor. Blosozumab stimulates bone formation and reduces bone resorption. Blosozumab can be used in the research of Osteoporosis[1][2].
Product Specifications
CAS Number
[1132758-87-2]
UNSPSC
12352203
Target
Others
Type
Inhibitory Antibodies
Related Pathways
Others
Field of Research
Others
Assay Protocol
https://www.medchemexpress.com/blosozumab.html
Purity
99.45
Solubility
10 mM in DMSO
Smiles
[Blosozumab]
Molecular Weight
(144.88 kDa)
References & Citations
[1]Robert R Recker, et al. A randomized, double-blind phase 2 clinical trial of blosozumab, a sclerostin antibody, in postmenopausal women with low bone mineral density. J Bone Miner Res. 2015 Feb;30 (2) :216-24. |[2]Daniel G Rudmann, et al. Rat-specific decreases in platelet count caused by a humanized monoclonal antibody against sclerostin. Toxicol Sci. 2012 Feb;125 (2) :586-94.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 2
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
![Rabbit Polyclonal EID1 Antibody [DyLight 680]](https://cdn.genprice.uk/genprice/uk/genprice5.webp)
![Rabbit Polyclonal EAAT1/GLAST-1/SLC1A3 Antibody [PerCP]](https://cdn.genprice.uk/genprice/uk/genprice4.webp)
129363-PE 100 µL
MAP1S (BPY2IP1, C19orf5, MAP8, VCY2IP1, Microtubule-associated Protein 1S, BPY2-interacting Protein 1, Microtubule-associated Protein 8, Variable Charge Y Chromosome 2-interacting Protein 1, MAP1S Heavy Chain, MAP1S Light Chain, FLJ10669, MGC133087) (PE)
Ask
View Details